Home > Protocol Summaries: Compounds > sumatriptan/naproxen Protocol Summaries: sumatriptan/naproxen GSKStudy ID Phase Title Status 107979 phase 3 TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents Completed 110948 phase 4 Assessment of the effect of sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, and naproxen sodium tablet treatment on blood pressure when administered intermittently for six months for the acute treatment of migraine attacks, with or without aura, in adults Completed 111208 phase 4 The Combination Product of Sumatriptan and Naproxen Sodium Pharmacy Budget Impact Model database validation study Completed 112617 phase 4 Impact of Migraine on Work Productivity in Patients Treated with a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy Completed 113913 phase 4 A Combination Product of Sumatriptan and Naproxen Sodium versus Single-entity Oral Triptans: An Analysis of Real World Data Completed MT400-108 Phase 1 Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets Administered Two Hours Apart on Chromosomal Aberrations in Peripheral Blood Lymphocytes Completed MT400-301 Phase 3 A Double-Blind Multicenter, Randomized, Placebo-Controlled Single dose study to evaluate the safety and efficacy of Trexima in the acute treatment of migrane headaches Completed MT400-302 Phase 3 A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy opf Trexima in the Acute Treatment of Migraine Headaches Completed MT400-303 Phase 3 An Open-Label, Repeat Dose Study Of The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months Completed TRX109011 phase 3 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2 Completed TRX109013 phase 3 A Crossover, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Evaluate the Efficacy of TREXIMET®/Sumatriptan + Naproxen Sodium vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during Moderate-Severe Migraine Pain, 2 of 2 Completed TXA107977 phase 3 Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents Completed
